News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  10 November 2015  
 
Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy
 
 




Authors
Ajaybabu V. Pobbati1,1,5,*, Xiao Han2,4,5, Alvin W. Hung4,5, Seetoh Weiguang4, Nur Huda4, Guo-Ying Chen4, CongBao Kang4, Cheng San Brian4, Xuelian Luo3,**, Wanjin Hong1 and Anders Poulsen 4,***

1 Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis Drive, Singapore 138673
2 Key Laboratory for Molecular Enzymology & Engineering, the Ministry of Education, School of Life   Sciences, Jilin University, Changchun, China, 130012
3 Department of Pharmacology, University of Texas Southwestern Medical Center, 6001 Forest Park   Road, Dallas, TX 75390, USA
4 Experimental Therapeutics Centre, A*STAR, 31 Biopolis Way, #3-01, Singapore 138669
5 Co-first author

*    Correspondence: ajaybabuvp@imcb.a-star.edu.sg
**  Correspondence: xuelian.luo@utsouthwestern.edu
*** Correspondence: apoulsen@etc.a-star.edu.sg

Published online in Structure on 22 October 2015.

Abstract
The human TEAD family of transcription factors (TEAD1-4) is required for YAP-mediated transcription in the Hippo pathway.  Hyperactivation of TEAD’s co-activator YAP contributes to tissue overgrowth and human cancers, suggesting that pharmacological interference of TEAD-YAP activity may be an effective strategy for anticancer therapy.  Here we report the discovery of a central pocket in the YAP-binding domain (YBD) of TEAD that is targetable by small molecule inhibitors.  Our X-ray crystallography studies reveal that flufenamic acid, a non-steroidal anti-inflammatory drug (NSAID), binds to the central pocket of TEAD2 YBD.  Our biochemical and functional analyses further demonstrate that binding of NSAIDs to TEAD inhibits TEAD-YAP-dependent transcription, cell migration and proliferation, indicating that the central pocket is important for TEAD function.  Therefore, our studies discover a novel way of targeting TEAD transcription factors and set the stage for therapeutic development of specific TEAD-YAP inhibitors against human cancers.

Figure:

Figure legend:
Structure of the TEAD2-flufenamic acid Complex
(A) Crystal structure of the TEAD2-FA complex reveals that FA binds to the central pocket in TEAD.  TEAD2 YBD is colored green.  FA is shown as pink sticks.
(B) A cross-section of the surface drawing of TEAD2 YBD shows FA occupying the central pocket.
(C) Simulated annealing omit map contoured at 1 s for FA. 
(D) Detailed view of the TEAD-FA interaction.  FA and FA-contacting residues in the central pocket are shown as pink and grey sticks, respectively.  The hydrogen bond between FA and C380 is shown as a green dash line.


For more information on Wanjin HONG 's laboratory, please click here.